Table 1.
Category | Therapeutic Drugs | FIP Guidance6 | Chinese Guidance7 | WHO Guidance8 | CDC Guidance9 | CPA Guidance13 | Clinical Research14, 15, 16, 17, 18, 19, 20, 21 |
---|---|---|---|---|---|---|---|
Antiviral | Lopinavir-Ritonavir | ●a | ● | – | – | ● | ▲c△d |
Arbidol | ● | ● | – | – | ● | ▲△ | |
Interferon | ● | ● | – | – | ● | – | |
Ribavirin | ● | ● | – | – | ● | – | |
Remdesivir | −e | – | – | – | – | – | |
Oseltamivir | – | – | – | – | – | – | |
Favipiravir | – | – | – | – | ● | – | |
Chloroquine phosphate | ● | ● | – | – | ● | – | |
Hydroxychloroquine sulfate | – | – | – | – | – | ▲△ | |
Immunomodulator | Corticosteroids | ◯b | ◯ | ◯ | ◯ | ◯ | △ |
Tocilizumab | ◯ | ◯ | – | – | – | – | |
Antimicrobials | Antibiotics | ◯ | ◯ | ◯ | – | ◯ | – |
●recommend.
◯recommend only if necessary.
▲significant effect.
△no significant difference compared with control group.
−not recommend or no current clinical research results.